Incyte Corp Ltd (INCY): Today's Featured Health Care Loser

Incyte ( INCY) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day up 1.1%. By the end of trading, Incyte fell 13 cents (-0.5%) to $25.47 on light volume. Throughout the day, 948,780 shares of Incyte exchanged hands as compared to its average daily volume of 1.8 million shares. The stock ranged in price between $25.28-$25.75 after having opened the day at $25.74 as compared to the previous trading day's close of $25.60. Other company's within the Health Care sector that declined today were: K-V Pharmaceutical Company ( KV.B), down 21.2%, Reliv' International ( RELV), down 13.6%, American Caresource Holdings ( ANCI), down 12.8%, and Ampio Pharmaceuticals ( AMPE), down 12.3%.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $3.12 billion and is part of the drugs industry. Shares are up 62.5% year to date as of the close of trading on Thursday. Currently there are 13 analysts that rate Incyte a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Incyte as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share.

On the positive front, Opexa Therapeutics ( OPXA), up 86%, IsoRay ( ISR), up 32.4%, Cormedix ( CRMD), up 19.1%, and Affymax ( AFFY), up 15.8%, were all gainers within the health care sector with Gilead ( GILD) being today's featured health care sector winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists